The organic cation transporters OCT and OCTN have been reported to play a significant role in the cellular uptake of substrates within in vitro lung cells. However, no studies to date have investigated the effect of these transporters upon transepithelial absorption of substrates into the pulmonary circulation. We investigated the contribution of OCT and OCTN transporters to total pulmonary absorption of L-carnitine and the anti-muscarinic drug, ipratropium, across an intact isolated perfused rat lung (IPRL). The results obtained from the IPRL were contrasted with active transport in vitro using three human pulmonary cell lines and primary rat alveolar epithelial cells. Ex-vivo studies showed that OCT/OCTN transporters do not play a role in the overall pulmonary absorption of L-carnitine or ipratropium, as evidenced by the effect of chemical inhibition of these transporters upon pulmonary absorption. In contrast, invitro studies showed that OCT/OCTN transporters play a significant role in cellular accumulation of substrates with preferential uptake of ipratropium by OCTs, and of Lcarnitine uptake by OCTNs. The results show that in-vitro uptake studies cannot be predictive of airway to blood absorption in-vivo. Nevertheless, localised submucosal pulmonary concentrations of inhaled drugs and their pulmonary pharmacodynamic profiles may be influenced by OCT/OCTN transport activity.
Introduction 1
A number of drug candidates for inhaled therapy are cationic and are therefore potential 2 substrates for the SLC22 superfamily of ATP-independent polyspecific cation transporters at 3 the plasma membrane [1] . These transporters include the bidirectional organic cation 4 transporters OCT 1 (SLC22A1), OCT2 (SLC22A2), OCT3 (SLC22A3) and the sodium-5 dependent carnitine/cation transporter proteins OCTN1 (SLC22A4) and OCTN2 (SLC22A5). 6
The majority of inhaled drugs must cross the rate-limiting pulmonary epithelial barrier to 7 access their pharmacological targets [2] , e.g. smooth muscle cells. As such the interaction of 8 cationic drugs with transporter pathways expressed in pulmonary epithelium may be 9 important for drug access to underlying pharmacological targets. Indeed this has been the 10 premise of research by a number of groups (reviewed in [3] [4] [5] ) exploring the expression of 11
OCTs/OCTNs within lung epithelium. 12
The localisation of OCT/OCTN transporters within intact lung has been reported using 13 protein immunohistochemistry in both humans [6] [7] [8] [9] and rodents [6, 8, 10, 11] . Evidence for 14 expression of OCT and OCTN family members in intact human and rat lung tissue also exists 15 at the mRNA level [6, 8, [11] [12] [13] . Nakanishi et al. [14] showed OCT/OCTN driven 16 accumulation of ipratropium in lung epithelial tissue, namely tracheal epithelium, following 17 drug deposition in the tracheal lumen of the mouse. A number of in vitro cell culture studies 18 have reported substrate uptake via OCTs and OCTNs in lung epithelial cells including the 19 active uptake of the model OCT/OCTN cationic substrate (4-(4-dimethylaminostyryl)-N-20 methylpyridinium; ASP + ) in normal human bronchial cells [7] and in a range of human 21 bronchial epithelial cell lines [15] [16] [17] . The inhaled anti-muscarinic drug ipratropium has been 22 implicated as a substrate of both OCTN and OCT transporters depending upon the in vitro 23 model adopted [18, 19] . One report exists of the facilitative role of organic cation 24 transporters upon the absorptive and secretory transport of ASP + across a cell monolayer [15] 25 with the results showing modest effects upon the overall absorptive transport, despite a 26 significant extent of cellular uptake. 27
Here we hypothesized that in a fully intact lung the OCT/OCTN transporters play little or no 28 role in the transepithelial transport of substrates into the pulmonary vasculature. To test the 29 hypothesis we examined in an intact perfused rat lung (IPRL) the role of OCT/OCTN 30 transport in pulmonary transepithelial permeability of the zwitterionic substrate, L-carnitine, 31 and the inhaled therapeutic cationic drug, ipratropium; archetype substrates for the pathways 32 under study. We found the overall solute transport into the IPRL vasculature was 33 predominantly driven by non-competitive passive processes that eclipse the net effect of any 34
OCT/OCTN-mediated transport. 35 To examine the transport of ipratropium and L-carnitine across an intact pulmonary barrier an 52 IPRL preparation was employed as previously described [20, 21] . This model includes an 53 intra-tracheal airway dosing technique that utilises a pressurized metered dose inhaler 54 (pMDI) reproducibly delivering a high extent (>95%) of deposited solute liquid aerosol dose 55 into the lung periphery [22] . Using the pMDI methodology the IPRL was dosed with either 56 vehicle control (100 µL saline) or a competitive inhibitor (in 100 µL saline), i. the uptake of radiolabel allowed to proceed over a 60 min incubation period. The solute 98 uptake experiments were terminated by two washes of the cell monolayers with ice-cold PBS 99
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followed by the addition of ice-cold trypsin-EDTA for 5 min, after which the cells were 100 harvested and suspended in ice-cold DMEM and centrifuged (4 °C, 200 g) for 10 min after 101 which the supernatant was discarded and the cell pellet collected. This cell washing 102 procedure was performed three times in total. The resulting cell pellets were transferred to 103 scintillation vials and mixed with 3mL of BioSafe 3 scintillation fluid and the cell-associated 104 radioactivity quantified by liquid scintillation counting. The sodium-dependent nature of 105 solute uptake for both [
3 H]-ipratropium and [ 3 H]-L-carnitine was similarly conducted but 106 using an incubation buffer where Na + was isotonically replaced with N-methyl-glucamine as 107 previously described [7] . 108 109
Real-time Quantitative Polymerase Chain Reaction (qPCR) 110
Human OCT (SLC22A1, SLC22A3, SLC22A3), human OCTN (SLC22A4, SLC22A5), rat 111 OCT (Slc22a1, Slc22a2, Slc22a3) and rat OCTN (Slc22a4, Slc22a5) mRNA sequences were 112 aligned using BLAST2 and the NCBI nucleotide gene search used to identify single exon 113 regions; Oligocalc was used to validate all used transcription variants. Table 1 shows the 114 primer sequences used in qPCR experiments. Total RNA was isolated (RNeasy, Qiagen, 115 UK) from pulmonary epithelial cells (A549, BEAS-2B, 16HBE14o -or primary rat alveolar 116 epithelial cells) grown under the same conditions as used in the solute uptake experiments. 117
Total RNA was also isolated from whole rat lung and liver tissue, with the liver serving as a 118 positive control that is known to express OCT/OCTN, albeit at different relative amounts. 119 cDNA synthesis was performed via reverse transcription using M-MLV reverse transcriptase 120 (Invitrogen, UK) using generic random oligonucleotide (pdN 6 ) primers and quantified 121 spectrophotometrically at 260 and 280 nm by GeneQuant. The cDNA was amplified as 122 described elsewhere [26] . qPCR was performed by SYBR ® Green chemistry using a DNA 123
Engine Opticon 2 Real-Time Cycler (BioRad, UK), previously described elsewhere [27] . The 124 increase in fluorescence emission associated with DNA amplification was calculated 125 throughout the run of 40 cycles and the cycle number at which fluorescence emission first 126 reaches exponential phase was recorded. 127 128
RESULTS 129
Pulmonary transepithelial transport of [ 3 H]-ipratropium and [ 3 H]-L-carnitine 130
We explored if OCT/OCTN-mediated transport was a significant feature in the transepithelial 131 absorption (airway to pulmonary vascular space) of Table  135 2). Pre-administration into the airways (20 min prior to that of radiolabelled substrate) of 125 136 nmol of the respective unlabelled solute (either unlabelled ipratropium or L-carnitine) failed 137 to significantly alter the extent or rate of absorption of the corresponding radiolabelled 138 species. This despite the unlabeled solute dosed at a 3000-fold excess to that of the 139 radiolabelled substrate. Similarly, pre-administration of 125 nmol of MPP + failed to alter 140 vitro lung epithelial cell-based studies which infer that these transporters may fulfill a role in 210 substrate access to sub-mucosal smooth muscle targets. 211
Here we used an IPRL system to study transepithelial absorption from the airways, a fully 212 intact whole lung model retaining the relevant in-vivo biological architecture and the various 213 sequential and parallel, e.g. paracellular, active/facilitative and passive transcellular routes 214 that may contribute to various extents a substrate's overall transepithelial penetration. We 215 have previously demonstrated that the IPRL can serve as a reliable and robust model that is 216 capable of discriminating active transport pathways for substrate movement across lung 217 epithelia. For example, we have shown in the IPRL that P-glycoprotein (P-gp) drug efflux 218 reduces the pulmonary absorption of certain P-gp substrates [28] , an efflux mechanism which 219 can be inhibited in the IPRL by co-administration of the chemical inhibitors such as elacridar 220 (GF-120918). The IPRL displays similar airway perfusion characteristics to the fully intact 221 in-vivo rat lung [29] [30] [31] . Indeed, in the IPRL the entire lung parenchyma from the secondary 222 bronchi (second airway bifurcation) to the deep alveolar regions is perfused by the pulmonary 223 circulation [30] , as it is in vivo. transporter-facilitated transport into the mucosal epithelia. Unwalla et al [38] reported that the 319 transepithelial transport of salbutamol is increased through relaxation of epithelia tight 320 junctional complexes that results from the b 2 -receptor mediated rises in intracellular cAMP 321 levels. This mechanism is not expected for ipratropium which acts via the M3 muscarinic 322 receptor. More likely is a complex and dynamic interplay between membrane transporters in 323 the epithelial and submucosal lung tissue that serve in concert to limit the access of select 324 solutes to the pulmonary vascular bed. 325 326
Conclusions 327
In conclusion we find no evidence for a role of OCT/OCTN in the absorption of L-carnitine 328 or ipratropium across an intact lung epithelial barrier into the pulmonary circulation. This is 329 despite evidence in cell lines, including primary cells from the same group of rats, that the 330 transporters play a significant role in the uptake of the substrates in to the epithelial cells. It 331 follows that the rate of delivery of such molecules from airspace to lung sub-mucosal tissue 332 in the intact organ will predominately be driven by passive processes. However, it is not 333 possible to conclude that OCT and/or OCTN transporters lack influence upon localised 334 submucosal pulmonary concentrations, and consequently upon the pharmacodynamic (PD) 335 profiles for airway-administered cationic drugs. Indeed, while OCT and/or OCTN 336 transporters may lack significant impact upon the aggregate systemic levels of inhaled 337 cationic drug, these transporters may still affect localised drug concentrations (e.g. recycling) 338 in the pulmonary PD compartment(s) which is an issue that necessitates further PK/PD 339 investigations in the future. 340 
